Trimetazidine dihydrochloride

Catalog No.S4543 Batch:S454303

Technical Data

Formula

C₁₄H₂₂N₂O₃.2HCl

Molecular Weight

339.26

CAS No.

13171-25-0

Solubility (25°C)*

In vitro

DMSO

68 mg/mL (200.43 mM)

Water

68 mg/mL (200.43 mM)

Ethanol

5 mg/mL (14.73 mM)

In vivo (Add solvents to the product individually and in order)

Clear solution

saline

50.0mg/ml

Taking the 1 mL working solution as an example, add 50 mg of this product to 1 ml of physiological saline (0.9% NaCL solution), mix evenly to make it clear, The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Trimetazidine dihydrochloride (Yoshimilon, Kyurinett, Vastarel F) is a kind of drug for treatment of chronic ischemic disorders. It improves myocardial glucose utilization through inhibition of fatty acid metabolism, known as fatty acid oxidation inhibitor.

Targets

mitochondrial long-chain 3-ketoacyl thiolase ^[1]
(Cell-free assay)

75 nM

In vitro

Trimetazidine up-regulates miR-21 expression, then miR-21 targets PTEN increasing the PI3K pathway and finally the activation of this pathway counteracts the apoptotic effect of hypoxia/reperfusion^[3].

In vivo

The administration of TMZ reduces myocardial infarction size in WT C57BL/6J hearts. Both AMPK and ERK signaling pathways mediate the cardioprotection of TMZ against ischemic injury. Trimetazidine Shifts Metabolism from Fatty Acid Oxidation to Glucose Oxidation and improves Contractile Functions of Cardiomyocytes during Hypoxia^[2].

Protocol (from reference)

Cell Assay:^{^[3]}	Cell lines human H9C2 cell line Concentrations 10 μM Incubation Time 48 h Method The H9C2 cells are randomly assigned into three groups: Sham group, in which the cells are treated with 0μM TMZ for 48 h and then cultured under normal oxygenation conditions (5% CO2, and 95% air); H/R group, in which cells are treated with 0 μM TMZ for 48 h and then cultured under H/R conditions; and H/R+TMZ group, in which cells are treated with 10 μM TMZ for 48 h and then subjected to H/R treatment.
Animal Study:^{^[2]}	Animal Models C57BL/6J, AMPK KD mice Dosages 0.5 mg/kg Administration tail vein injection

Cell Assay:^{^[3]}

Cell lines
human H9C2 cell line
Concentrations
10 μM
Incubation Time
48 h
Method
The H9C2 cells are randomly assigned into three groups: Sham group, in which the cells are treated with 0μM TMZ for 48 h and then cultured under normal oxygenation conditions (5% CO2, and 95% air); H/R group, in which cells are treated with 0 μM TMZ for 48 h and then cultured under H/R conditions; and H/R+TMZ group, in which cells are treated with 10 μM TMZ for 48 h and then subjected to H/R treatment.

Animal Study:^{^[2]}

Animal Models
C57BL/6J, AMPK KD mice
Dosages
0.5 mg/kg
Administration
tail vein injection

References

Selleck's Trimetazidine dihydrochloride has been cited by 7 publications

Mindin Activates Autophagy for Lipid Utilization and Facilitates White Spot Syndrome Virus Infection in Shrimp [ mBio, 2023, e0291922.]	PubMed: 36779788
Repurposing of Trimetazidine for amyotrophic lateral sclerosis: A study in SOD1G93A mice [ Br J Pharmacol, 2022, 179(8):1732-1752]	PubMed: 34783031
Repurposing of Trimetazidine for amyotrophic lateral sclerosis: A study in SOD1G93A mice [ Br J Pharmacol, 2022, 179(8):1732-1752]	PubMed: 34783031
Trimetazidine affects pyroptosis by targeting GSDMD in myocardial ischemia/reperfusion injury [ Inflamm Res, 2022, 10.1007/s00011-021-01530-6]	PubMed: 34993560
QiShenYiQi Pill Ameliorates Cardiac Fibrosis After Pressure Overload-Induced Cardiac Hypertrophy by Regulating FHL2 and the Macrophage RP S19/TGF-β1 Signaling Pathway [ Front Pharmacol, 2022, 13:918335]	PubMed: 35910357
QiShenYiQi Pill Ameliorates Cardiac Fibrosis After Pressure Overload-Induced Cardiac Hypertrophy by Regulating FHL2 and the Macrophage RP S19/TGF-β1 Signaling Pathway [ Front Pharmacol, 2022, 13:918335]	PubMed: 35910357
The role of PAK1 in the sensitivity of kidney epithelial cells to ischemia-like conditions. [ Cell Cycle, 2019, 18(5):596-604]	PubMed: 30724698

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.